Stefano Gullà

CSO at Kling Bio | scientist-entrepreneur | building new medicines

Amsterdam, North Holland, Netherlands

About

Results-oriented biotech and pharma executive with demonstrated success discovering and developing new therapeutic technologies. I’ve dedicated my professional focus towards developing novel approaches to treat cancer and autoimmune disorders.

Experience

  • Chief Scientific Officer at Kling Biotherapeutics
    Sep 2023 - Present · 2 yrs 10 mos

  • VP, Biology Head, Protein Therapeutics at RVAC Medicines
    Jul 2022 - Aug 2023 · 1 yr 2 mos

  • Sr. Director Pharmacology and Preclinical Development at Repertoire Immune Medicines
    Mar 2021 - Jul 2022 · 1 yr 5 mos

  • CEO/CSO/Founder at Abcuro, Inc
    Nov 2016 - Jan 2021 · 4 yrs 3 mos

    Leveraging extensive biotech and pharma industry know-how, founded an innovative organization committed to developing a new class of immune modulatory bio-therapeutics for treating autoimmunity and cancer. Serving as founding CEO, directed all activities related to licensing of foundational IP, guiding discovery and development processes to bring novel biotherapeutics to clinic. • Led the development of two first-in-class biotherapeutic antibodies, guiding research and development from initial target validation to antibody discovery and IND enabling studies • Guided funding activities, raising over $50M in venture capital funding and non-dilutive grants • Directed global operations for a semi-virtual organizational model

  • Preclinical Portfolio Manager at Agenus
    Jun 2015 - Nov 2016 · 1 yr 6 mos

    Managed a portfolio of pre-clinical immuno-oncology programs, ensuring a rapid path from initial research to clinic. Guided program teams from ideation to IND. • Created project plans and timelines to guide technical teams through lead identification, lead optimization, and pre-clinical development. • Developed project budgets, strategically justifying expenditures and ensuring adherence to established financials. • Managed the activities of external vendors and CROs, negotiating key contracts and performing due diligence to protect organizational interests.